The Mesothelioma Center News – Page 21
-
Treatment & DoctorsThe U.S. Social Security Administration has added pericardial mesothelioma to its Compassionate Allowances list, accelerating the disabilities application process for this very rare…
-
Research & Clinical Trials
Duke Study Suggests Radiation Does Not Extend Mesothelioma Survival
A dual registry analysis by the esteemed Duke University Medical Center has concluded that adjuvant hemithoracic radiation does not improve survival when… -
Legislation & Litigation
J&J Facing Scrutiny from Congress, Black Women’s Organization
Plaintiff attorneys and congressional leaders have renewed their push against Johnson & Johnson and its allegedly toxic, talc-based powder products, questioning motives and… -
Research & Clinical Trials
FDA Grants Orphan Drug Designation to Novel Mesothelioma Treatment
The U.S. Food and Drug Administration has granted orphan drug designation to ONCOFID-P for the treatment of malignant pleural mesothelioma, a step… -
Research & Clinical Trials
Researcher Hopes to Improve Tumor Treating Fields for Mesothelioma
Dr. Maurizio D’Incalci already has seen Tumor Treating Fields working for patients with malignant pleural mesothelioma, and applauded the U.S. Food and… -
Research & Clinical Trials
CAR T-Cell Therapy Showing Promise with Pleural Mesothelioma
Memorial Sloan Kettering Cancer Center continues its drive toward a future that may involve innovative CAR T-cell therapy as part of standard-of-care treatment… -
Legislation & Litigation
Johnson & Johnson Weighs Options for Talc Liabilities
Johnson & Johnson is considering the creation of a new subsidiary to absorb its widespread asbestos liabilities, according to reports in The Wall… -
Research & Clinical Trials
New Drug Combination Shows Promise for Peritoneal Mesothelioma
Researchers at MD Anderson Cancer Center in Houston have uncovered a new, promising treatment option for patients with peritoneal mesothelioma, potentially filling… -
Research & Clinical Trials
Mesothelioma Research Grants Focus on Immunotherapy
It comes as no surprise that immunotherapy is the common theme of the latest batch of the Mesothelioma Applied Research Foundation’s $100,000 grants. -
Research & Clinical Trials
GPS Vaccine Plus Opdivo Shows Promise for Pleural Mesothelioma
A novel, targeted cancer vaccine combined with the immunotherapy drug Opdivo has shown surprising efficacy for mesothelioma patients whose disease no longer…